Liyan Mazahreh

Role not yet determined Is this you? Add your title

UAMS

Also affiliated: Hashemite University (2023); Central Arkansas Veterans Healthcare System (2023)

3 h-index 14 pubs 161 cited

Research Areas

Biomedical Subjects

OverviewAI-generated summary

Liyan Mazahreh's research focuses on the clinical aspects of various medical conditions, with a significant emphasis on hematologic malignancies and infectious disease risks. Recent publications investigate the safety profiles of bispecific antibodies in multiple myeloma, examining the incidence and severity of associated infections. Mazahreh also studies patient outcomes in oncology, including responses to immune-oncology therapies and the duration of immune checkpoint inhibitors. Further work explores exacerbations of asthma in children during periods of non-pharmaceutical interventions and investigations into chronic rhinosinusitis. Mazahreh has a h-index of 3 with 160 citations across 14 publications. Key collaborators include Farah Mazahreh, Ahmad Mazin M. Safar, Brad Fugere, and Fenghuang Zhan, all from the University of Arkansas for Medical Sciences, with whom Mazahreh shares multiple publications.

Metrics

h-index: 3
Publications: 14
Citations: 161

Selected Publications

Abstract 3051: Enhancing matchmaking in targeted therapy (TT) for cancer (ca): Beyond the ‘arranged’ criteria (2026)

Cancer Research DOI OpenAlex
Abstract 6288: Rational pairing of tumors with off-patent targeted therapies (TT): Next3 generation sequencing with global applications for the unprivileged patients. (2026)

Cancer Research DOI OpenAlex
Hospitalizations and Severity of Rhinovirus-Associated Asthma Exacerbations in Children During the Institution of Non-pharmaceutical Interventions (2026)

Journal of Allergy and Clinical Immunology DOI OpenAlex
Exploring new frontiers in eosinophilic chronic rhinosinusitis (2025)

Annals of Allergy Asthma & Immunology DOI OpenAlex
Abstract 3214: The duration of immune checkpoint inhibitors (ICI) in oncology: Longer is not better (2025)

Cancer Research DOI OpenAlex
Ongoing Radiographic Response for Over 20 Months in Metastatic Cancer Without Continued Immune Checkpoint Inhibitor (ICI) Dosing (2025)

Cureus DOI OpenAlex
Tumor Response to Immune-Oncology Therapy Despite High-Dose Steroid Intervention in a Patient With Papillary Renal Cell Carcinoma and Immune-Related Myasthenia Gravis (2025)

Cureus 2 citations DOI OpenAlex
Abstract 1177: The chronology of immune-related adverse events (irAEs)-mechanistic implications (2024)

Cancer Research DOI OpenAlex